Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target raised by UBS Group from $28.00 to $30.00 in a research note published on Thursday,Benzinga reports. UBS Group currently ...

The biopharma industry is highly dynamic and competitive. Companies that succeed in it must be able to tackle various aspects, including finances, marketing, regulations, investor relations, ...

Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.

The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.

Utah will receive $57 million to combat the state’s opioid crisis if it joins the $7.4 billion settlement against the Sackler ...

By August or September of this year, Petersen said he expects “basically half” of the company’s $8 billion in manufacturing ...

Industry leaders are hopeful that DEI will remain a priority for enhanced audience engagement, but fear that it will not stay ...

Minot Light Capital, an investment management firm, recently released its fourth-quarter 2024 investor letter. A copy of the ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.